Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of Recombinant Human Nerve Growth Factor in Patients With Stage 2 and 3 of NK

NCT01756456 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT01756456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01756456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of Recombinant Human Nerve Growth Factor in Patients With Stage 2 and 3 of NK
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2013
Completion date
May 31, 2016
Enrollment
174 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

corneal ulcer, keratitis, neurotrophic keratitis